Thioredoxin, adiponectin and clinical course of acute fulminant myocarditis

Heart

Volumn 97, Issue 13, 2011, Pages 1067-1073

  Choi, Jin Oh ^a   Yun, Soo Hyeon ^a   Sung, Kiick ^b   Lee, Young Tak ^b   Park, Joong Il ^c   Ju, Eun Seon ^a   Lee, Sang Chol ^a   Park, Seung Woo ^a   Kim, Duk Kyung ^a   Oh, Jae K ^a,d   Jeon, Eun Seok ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Seoul Veterans Hospital   (South Korea)

^d Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; THIOREDOXIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSISTED CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; FULMINANT MYOCARDITIS; HEART TRANSPLANTATION; HUMAN; MALE; MYOCARDITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ACUTE DISEASE; ADIPONECTIN; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CYTOKINES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; PROGNOSIS; THIOREDOXINS; VIRUS DISEASES; YOUNG ADULT;

EID: 79958000417     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.219568     Document Type: Article

References (28)

1. Lieberman EB, Hutchins GM, Herskowitz A, et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991;18:1617-26.
2. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000;342:690-5. (Pubitemid 30131421)
3. Idelchik GM, Loyalka P, Kar B. Percutaneous ventricular assist device placement during active cardiopulmonary resuscitation for severe refractory cardiogenic shock after acute myocardial infarction. Tex Heart Inst J 2007;34:204-8. (Pubitemid 47066599)
4. Oshima K, Kunimoto F, Takahashi T, et al. Factors for successful weaning from a percutaneous cardiopulmonary support system (PCPS) in patients with low cardiac output syndrome after cardiovascular surgery. Int Heart J 2007;48:743-54.
5. Shin JS, Lee SW, Han GS, et al. Successful extracorporeal life support in cardiac arrest with recurrent ventricular fibrillation unresponsive to standard cardiopulmonary resuscitation. Resuscitation 2007;73:309-13.
6. Oshima K, Kunimoto F, Hinohara H, et al. Fulminant myocarditis treated with percutaneous cardiopulmonary support system (PCPS). Ann Thorac Cardiovasc Surg 2008;14:75-80.
7. Kishimoto C, Shioji K, Nakamura H, et al. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J 2001;65:491-4.
8. Miyamoto M, Kishimoto C, Shioji K, et al. Difference in thioredoxin expression in viral myocarditis in inbred strains of mice. Jpn Circ J 2001;65:561-4.
9. Shioji K, Nakamura H, Masutani H, et al. Redox regulation by thioredoxin in cardiovascular diseases. Antioxid Redox Signal 2003;5:795-802. (Pubitemid 37462063)
10. Takahashi T, Yu F, Saegusa S, et al. Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. Int Heart J 2006;47:107-23.
11. Saegusa S, Fei Y, Takahashi T, et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther 2007;21:155-60. (Pubitemid 46817480)
12. Yu F, Chen R, Takahashi T, et al. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Int J Cardiol 2007;129:414-21.
13. Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J 2002;66:133-44. (Pubitemid 34464719)
14. Chen YS, Yu HY, Huang SC, et al. Experience and result of extracorporeal membrane oxygenation in treating fulminant myocarditis with shock: what mechanical support should be considered first? J Heart Lung Transplant 2005;24:81-7.
15. Sasaki H, Kawai A, Kurosawa H. Mechanical support for patients with fulminant acute myocarditis: strategy for biventricular failure and respiratory failure. J Card Surg 2008;23:526-7.
16. Ohkawa M, Nishikawa K, Takazawa T, et al. [Successful management of a man with fulminant myocarditis using percutaneous cardiopulmonary support]. Masui 2005;54:172-6.
17. Furukawa N, Hata M, Sezai A, et al. Successful treatment of fulminant myocarditis with mechanical circulatory support. J Card Surg 2008;23:570-2.
18. Idelchik GM, Simpson L, Civitello AB, et al. Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device implantation. J Heart Lung Transplant 2008;27:106-11.
19. Jaroszewski DE, Marranca MC, Pierce CN, et al. Successive circulatory support stages: a triple bridge to recovery from fulminant myocarditis. J Heart Lung Transplant 2009;28:984-6.
20. Shioji K, Matsuura Y, Iwase T, et al. Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thioredoxin: a case report. Circ J 2002;66:977-80.
21. Nishii M, Inomata T, Takehana H, et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 2004;44:1292-7. (Pubitemid 39208887)
22. Dieplinger B, Gegenhuber A, Haltmayer M, et al. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 2009;95:1508-13.
23. Unno K, Shibata R, Izawa H, et al. Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Heart 2010;96:357-61.
24. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83. (Pubitemid 29299050)
25. Koenig W, Khuseyinova N, Baumert J, et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006;48:1369-77. (Pubitemid 44436825)
26. Tao L, Gao E, Jiao X, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007;115:1408-16. (Pubitemid 46648376)
27. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62. (Pubitemid 41372115)
28. Takahashi T, Saegusa S, Sumino H, et al. Adiponectin replacement therapy attenuates myocardial damage in leptin-deficient mice with viral myocarditis. J Int Med Res 2005;33:207-14. (Pubitemid 40372436)